Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Abbott Laboratories

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, moved higher by 0.21% ...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 5/26/2026

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, closed higher by 1.80%...

Schwab U.S. Dividend Equity ETF (SCHD) Latest Update

Walmart ($WMT), Abbott Laboratories ($ABT), and NextEra Energy ($NEE) are the three dividend aristocrat stocks with a Strong Buy rating on Wall Str...

3 ‘Strong Buy’ Dividend Aristocrat Stocks with 15%+ Upside, 5/22/26

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, moved higher by 0.50% ...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 5/22/2026

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, inched lower by 0.03% ...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 5/20/2026

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Abbott Laboratories (ABT) and BioMarin Pharmaceutica...

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and BioMarin Pharmaceutical (BMRN)

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, was down by 0.06% in e...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 5/18/2026

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, was down by 0.09% in e...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 5/15/2026

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, was up by 0.51% in pre...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 5/8/2026

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories yesterday and set a price target of $109.00. Biegelsen covers th...

Wells Fargo Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, was up by 0.16% in pre...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 5/5/2026

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, was down by 0.19% in p...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 5/4/2026

Insiders have been trading these 5 stocks: (($AGNC)), (($LRCX)), (($ABT)), (($BLK)) and (($SLB)). Here is a breakdown of their recent trades and th...

AGNC, Lam, Abbott, BlackRock, Schlumberger: Insider Shockwave

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, was up by 0.10% in pre...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/30/2026

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, was up by 0.55% in pre...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/28/2026

Abbott Laboratories ( ($ABT) ) has shared an announcement. On April 24, 2026, Abbott Laboratories expanded its board to 13 members and appointed Ke...

Abbott Expands Board and Enhances Equity Incentive Programs

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, was up by 0.42% in pre...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/27/2026

Citi analyst Joanne Wuensch reiterated a Buy rating on Abbott Laboratories yesterday and set a price target of $108.00. Wuensch covers the Healthca...

Market Cap	$154.71B	P/E Ratio	15.82
52W High	$139.06	52W Low	$81.97
Div Yield	252.0%	Payout Ratio	66.9%
EPS Growth 3Y	-1.8%	52W Position	8.3%
Overall Score	51	Value Score	90
Quality Score	47	Technical Score	18

EPS Current Est	$5.48	EPS Next Est	$6.06
EPS Growth Est	+10.6%	DPS Growth 3Y	8.5%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABT	$86.70	-0.81%	6.90M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABT	$86.70	-0.8%	6.90M
3
4
5
6

ABT

ABT

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Abbott Laboratories Data in Excel

Get Abbott Laboratories Data in Excel